NASDAQ · UBX
Healthcare · Biotechnology
$0.20
Up+$0.10 (+92.77%)
Updated Aug 18, 2026, 2:16 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
UBX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning UBX.
UBX research
Company profile and research snapshot.
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 27, 2025 | HC Wainwright & Co. | Neutral | — |
| Apr 23, 2025 | Chardan Capital | Buy | — |
| Apr 23, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 25, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 25, 2025 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Zacks Investment Research · May 17, 2024
UNITY Biotechnology (UBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GlobeNewswire Inc. · Apr 15, 2024
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates.
Benzinga · Nov 16, 2023
Wedbush analyst Andreas Argyrides upgraded the shares of Unity Biotechnology Inc (NASDAQ: UBX) from Neutral to Outperform and raised the price target from $2 to $4. Unity Biotechnology is developing therapeutics to slow, halt or reverse diseases of aging. Unity's initial focus is on creating medicines that target cellular senescence and aging-related biology in ophthalmologic and neurologic diseases. Following the positive 12 week, 18 week, 24 week and 48 week results from the Ph2 BEHOLD trial for UBX1325/DME, the company is set to initiate a head-to-head Ph2b trial for UBX1325 against aflibercept in patients with DME later ...Full story available on Benzinga.com
GlobeNewswire Inc. · Nov 13, 2023
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2023.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning UBX.
No results
No recent SID articles mention UBX.
